Efficacy and Safety of Secukinumab Combined with Calcipotriol Ointment in the Treatment of Moderate to Severe Plaque Psoriasis
Objective:To explore the efficacy and safety of Secukinumab combined with Calcipotriol Ointment in the treatment of moderate to severe plaque psoriasis.Method:A total of 126 patients with moderate to severe plaque psoriasis admitted to Huai'an Cancer Hospital from February 2022 to December 2023 were selected.According to the random number table method,they were divided into Secukinumab group,Calcipotriol group,and Combination group,with 42 cases in each group.The Secukinumab group was treated with Secukinumab,the Calcipotriol group was treated with Calcipotriol,and the combination group was treated with Secukinumab combined with Calcipotriol.The score related indicators,immune indicators,inflammatory factors,metabolic function indicators before and after 12 weeks of treatment,and adverse reactions among three groups were compared.Result:After 12 weeks of treatment,the psoriasis area and severity index(PASI),silver chip disease body surface area severity score(BSA),and skin disease quality of life index score(DLQI)scores of the three groups all decreased,the PASI,BSA,and DLQI scores of the combination group were lower than those of the Secukinumab group and the Calcipotriol group,the PASI,BSA,and DLQI scores of the Secukinumab group were all lower than those of the Calcipotriol group,and the differences were statistically significant(P<0.05).After 12 weeks of treatment,CD4+levels increased,while CD8+,interleukin-2(IL-2),and interleukin-17(IL-17)levels decreased in all three groups,the combination group had higher CD4+levels and lower CD8+,IL-2,and IL-17 levels compared to the Secukinumab group and Calcipotriol group,the Calcipotriol group had lower CD4+levels and higher IL-2 and IL-17 levels than the Secukinumab group,the differences were statistically significant(P<0.05).After 12 weeks of treatment,there was no statistically significant difference in triglycerides(TG),total cholesterol(TC),uric acid(UA),alanine aminotransferase(ALT),and aspartate aminotransferase(AST)among the three groups(P>0.05).There was no statistically significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion:The combination of Secukinumab and Calcipotriol Ointment in treating moderate to severe plaque psoriasis is more effective than using either drug alone,with good safety.
万方数据
维普
